| Date | Title | Description |
| 06.11.2024 | Biotech companies report progress in clinical trials |
Following the sale of its lead molecule NM26 to Johnson & Johnson for USD 1.25 billion in May, Numab Therapeutics announced the start of a Phase 1 clinical trial evaluating NM32, a next generation tri-specific immuno-oncology therapeut... |
| 31.05.2024 | Forbion's Billion-Dollar Sale to Johnson & Johnson: A Landmark Achievement in Biotech Innovation | The recent announcement of Forbion's sale of Yellow Jersey Therapeutics to Johnson & Johnson for a staggering $1.25 billion has sent shockwaves through the biotech industry. This monumental deal, which includes the acquisition of rights... |
| 30.05.2024 | Numab Therapeutics' spin-off, Yellow Jersey Therapeutics, gets acquired by Johnson & Johnson for USD 1.25 billion | Numab Therapeutics' spin-off, Yellow Jersey Therapeutics, gets acquired by Johnson & Johnson for USD 1.25 billion 30.05.2024 10:06, Rita Longobardi linkedIn facebook twitter instagram youtube -->
Numab Therapeutics has agreed to sell... |
| 28.05.2024 | Forbion Announces $1.25 Billion Sale to Johnson & Johnson of Numab Therapeutics Subsidiary, Including Rights to NM26, a Bi-specific Antibody for the Treatment of Atopic Dermatitis, Marking its Six... | • Forbion announces the sale of Yellow Jersey Therapeutics, a wholly owned subsidiary to be spun off from its portfolio company Numab Therapeutics, an investment of Forbion’s Growth Opportunities Fund I
• This is Forbion's sixth consecutive... |
| 28.05.2024 | Johnson & Johnson acquires Numab spin-off for USD 1.25 billion |
Numab Therapeutics AG based in Horgen (ZH) is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Johnson & Johnson will acquire global rights to Numabs lead molecule NM26, a Phase 2-ready investigatio... |
| 20.10.2023 | Early-stage pharmaceutical companies make strides in cancer- and immunotherapy | |
| 15.05.2023 | Numab TherapeutIcs doses first patient with eczema | |
| 04.04.2022 | Numab signs a CHF 258 million deal with Ono Pharmaceuticles | |
| 20.05.2021 | Numab Therapeutics Completes CHF 100 Million Series C Financing | |
| 20.05.2021 | Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing | Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, today announced the closing of a CHF 100 million (approximately USD 110 m... |
| 20.05.2021 | Numab Therapeutics Completes CHF 100 Million Series C Financing | Numab Therapeutics aims to write the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. Its lead product was designed to balance potent anti-tumor immunity wit... |
| 20.05.2021 | Numab raises $111M to challenge Genmab, BioNTech for emerging PD-L1 opportunity | Numab Therapeutics has raised CHF 100 million ($111 million) to expand clinical development of its lead PD-L1x4-1BB drug candidate into multiple cancer indications. Novo Ventures and HBM Partners co-lead the series C round with assists from... |
| 20.05.2021 | Numab Therapeutics completes oversubscribed CHF 100 million Series C financing | Numab Therapeutics completes oversubscribed CHF 100 million Series C financing 20.05.2021 17:35, Isabelle Mitchell linkedIn facebook twitter instagram youtube -->
Numab Therapeutics, a clinical-stage biopharmaceutical company developing ... |
| 13.01.2021 | Numab Therapeutics signs co-development partnership with Japanese Pharma | |
| 13.01.2021 | Numab Therapeutics signs co-development partnership with Japanese Pharma | Numab Therapeutics is an oncology-focused biopharmaceutical company is developing multi-specific antibodies that enable the pursuit of novel therapeutic strategies based on its proprietary MATCH technology platform. The company has a broad ... |
| 05.10.2020 | Startups win strong and well-connected board members | NBE Therapeutics, Erich Schlick, chairman of the board of Director
NBE-Therapeutics, a biotech company developing best-in-class cancer therapies based on its proprietary, highly differentiated Antibody Drug Conjugate (ADC) platform, announc... |
| 05.10.2020 | Startups win strong and well-connected board members | |
| 24.08.2020 | Numab Therapeutics advances to the clinical trials stage | Numab Therapeutics is an oncology-focused biopharmaceutical company is developing multi-specific antibodies that enable the pursuit of novel therapeutic strategies based on its proprietary MATCH technology platform. Numab’s lead candidate, ... |
| 24.08.2020 | Numab Therapeutics advances to the clinical trials stage | |
| 09.07.2020 | Boehringer Ingelheim to Develop Antibody Therapeutics with Numab | Numab Therapeutics and Boehringer Ingelheim today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and ga... |
| 09.07.2020 | Boehringer Ingelheim to Develop Antibody Therapeutics with Numab | |
| 30.03.2020 | Numab Therapeutics to receive additional CHF 260M from its Japanese partner | The Zurich based Numab Therapeutics is focusing on the development of multi-specific antibodies based on its proprietary MATCH technology platform for the treatment of several cancers. The company’s lead oncology program ND021 was designed ... |
| 30.03.2020 | Numab Therapeutics to receive additional CHF 260M from its Japanese partner | |
| 09.03.2020 | Mitsubishi joins Eisai, 3SBio's bet on multispecific antibodies, upping Numab's Series B haul to $23M+ | Following a busy year of dealmaking, Swiss antibody shop Numab has closed a Series B at CHF22 million ($23.87 million) to double down on its multispecific molecules for immuno-oncology and grow its team.
Daniel Vasella... |
| 09.03.2020 | Vasella helps Numab to CHF22M round ahead of cancer trial start | Numab Therapeutics has raised CHF 22 million ($23.8 million) ahead of the start of clinical testing of its lead oncology drug ND021. Daniel Vasella, the former CEO of Novartis, was among the people to participate in the financing round.
In ... |
| 09.03.2020 | Numab Therapeutics raises CHF 22M series B round | Numab Therapeutics is an oncology-focused biopharmaceutical company developing a pipeline of multi-specific biotherapeutics in immuno-oncology and immunology for the treatment of severe diseases. With the new funds raised in a Series B roun... |
| 09.03.2020 | Swiss Biotech Numab Therapeutics raises CHF 22 million | Swiss Biotech Numab Therapeutics raises CHF 22 million 09.03.2020 15:38, Gianmaria Sbetta linkedIn facebook twitter instagram youtube -->
Numab Therapeutics announced today the closing of its Series B financing round at a total volume of... |
| 09.03.2020 | Numab Therapeutics raises CHF 22M series B round | |
| 09.03.2020 | Vasella helps Numab to CHF22M round ahead of cancer trial start | Numab Therapeutics has raised CHF 22 million ($23.8 million) ahead of the start of clinical testing of its lead oncology drug ND021. Daniel Vasella, the former CEO of Novartis, was among the people to participate in the financing round.
Spo... |
| 09.03.2020 | MUFG Capital joins Zurich-based Numab Therapeutics’ $22.6m Series B | Premium
Zurich-based biotech company Numab Therapeutics has snagged a total of $22.6 million in its Series B financing from a number of Asian investors as well as its board member, Dr. Daniel Vasella.
Continue reading this story with a subs... |
| 17.12.2019 | Biotech Startup Numab Therapeutics Raises CHF 15 Series B Round | Biotech Startup Numab Therapeutics Raises CHF 15 Series B Round 17.12.2019 13:52, Gianmaria Sbetta linkedIn facebook twitter instagram youtube -->
Swiss Biotech company Numab Therapeutics has announced the closing of it's CHF 15 million ... |
| 13.12.2019 | A new partner and investor for Numab | |
| 16.10.2019 | Daniel Vasella joins biotech startup | |
| 01.10.2019 | Eisai teams up with Numab to generate cancer therapeutics | |
| 03.05.2019 | Numab signs licensing deal with Chinese biopharmaceutical company | |
| 15.09.2017 | Intarcia and Numab Reach Key Milestone | |
| 16.06.2017 | Numab achieves milestones and signs new partnerships | |
| 29.03.2017 | Profitable deal for Numab | |
| 09.06.2015 | Tillotts and Numab conclude license agreement | |
| 20.03.2015 | Intarcia and Numab to develop once-yearly therapies in diabetes, obesity and autoimmune indications | |
| 12.06.2014 | Milestone payment for Numab | |
| 30.10.2013 | Numab Reacquires Advanced Compound from Sucampo | |
| 25.10.2013 | CEO Day 2013: a huge and efficient event - updated | |
| 31.07.2013 | Robert Kamen Joins Numab’s Advisory Board | |
| 19.03.2013 | Numab Earns Milestone Payment from Sucampo | |
| 18.12.2012 | Numab Nominates Burkhard Becher Scientific Advisor | In 2003 Burkhard was recruited as Assistant Professor to the University Hospital of Zurich and in 2008, he became full professor and co-chair at the Institute of Experimental Immunology at the University of Zurich. His fundamental contribut... |
| 07.12.2012 | More start-ups than ever at the Swiss Venture Day | |
| 23.11.2012 | Eight promising start-ups present at the next Swiss Venture Day | |
| 20.06.2012 | CTI Start-up Label for Numab, Qvanteq, SwissTV and Virometix | |
| 12.06.2012 | Grow Wädenswil im Aufwärtstrend | |
| 06.02.2012 | Ex-Esbatech employees are building up a new company | |
